Cornelia Quadt
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Journal: Targeted oncology
Published: August 31, 2023
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Journal: Breast cancer research : BCR
Published: August 18, 2023
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.
Journal: Nature
Published: July 26, 2023
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Journal: JAMA oncology
Published: December 14, 2018
A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: June 13, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
Journal: Cancer chemotherapy and pharmacology
Published: April 26, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 06, 2018
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
Journal: OncoTargets and therapy
Published: January 22, 2016
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
Journal: Nature
Published: April 29, 2014
Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.
Journal: British journal of clinical pharmacology
Published: November 25, 2013
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Journal: Cancer science
Published: September 15, 2013
Last Updated: 09/26/2026